The study included 110 patients who had previously received prior treatment with a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody; 78% of patients (86/110) had received at least 4 prior treatment regimens, and at least half of patients had received at least 5 prior treatment regimens.
Of the patients in the clinical trial who responded to TECVAYLI® (68/110), half began seeing results within approximately 1.2 months of starting treatment. The time until patients started to see results ranged from 0.2 months to 5.5 months.